Want to see FULC full AI Analyst Report?
Fulcrum Therapeutics (FULC) Stock Forecast & Price Target
FULC Analyst Ratings
FULC Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Gregory Renza | Truist Financial | ― | hold | ― | Reiterated | 08/18/26 | ||
| Tazeen Ahmad | Bank of America Securities | $3 | sell | -18.48%Downside | Reiterated | 08/07/26 | ||
| Edward Tenthoff | Piper Sandler | $23→$3 | sell | -18.48%Downside | Downgraded | 06/02/26 | ||
| Joseph Schwartz | Leerink Partners | $24→$4 | hold | 8.70%Upside | Downgraded | 06/02/26 | ||
| Andrew Fein | H.C. Wainwright | $25→$3 | hold | -18.48%Downside | Downgraded | 06/02/26 | ||
| Anupam Rama | J.P. Morgan | ― | sell | ― | Downgraded | 06/02/26 | ||
| Luca Issi | RBC Capital | $10→$4 | hold | 8.70%Upside | Reiterated | 06/02/26 | ||
| Kristen Kluska | Cantor Fitzgerald | $24 | buy | 552.17%Upside | Reiterated | 03/19/26 | ||
| Matthew Biegler | Oppenheimer | $15 | buy | 307.61%Upside | Reiterated | 12/08/25 | ||
 Unknown AnalystNot Ranked | Roth MKM | $15 | buy | 307.61%Upside | Reiterated | 12/08/25 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Gregory RenzaTruist Financial | HoldReiterated | 08/18/26 | ― | ||
| Tazeen AhmadBank of America Securities | SellReiterated$3 | 08/07/26 | -18.48%Downside | ||
| Edward TenthoffPiper Sandler | SellDowngraded$23→$3 | 06/02/26 | -18.48%Downside | ||
| Joseph SchwartzLeerink Partners | HoldDowngraded$24→$4 | 06/02/26 | 8.70%Upside | ||
| Andrew FeinH.C. Wainwright | HoldDowngraded$25→$3 | 06/02/26 | -18.48%Downside | ||
| Anupam RamaJ.P. Morgan | SellDowngraded | 06/02/26 | ― | ||
| Luca IssiRBC Capital | HoldReiterated$10→$4 | 06/02/26 | 8.70%Upside | ||
| Kristen KluskaCantor Fitzgerald | BuyReiterated$24 | 03/19/26 | 552.17%Upside | ||
| Matthew BieglerOppenheimer | BuyReiterated$15 | 12/08/25 | 307.61%Upside | ||
| Unknown AnalystRoth MKMNot Ranked | BuyReiterated$15 | 12/08/25 | 307.61%Upside |
Best Analysts Covering Fulcrum Therapeutics
Copying Matthew Biegler's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +4.92% per trade.
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.97% per trade.
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +27.88% per trade.
FULC Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 4 | 1 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 7 | 8 | 3 | 2 |
| Sell | 4 | 4 | 4 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 15 | 12 | 12 | 4 | 3 |
In the current month, FULC has received 0 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. FULC average Analyst price target in the past 3 months is ―.
FULC Financial Forecast
FULC Sales Forecast
Next quarter’s sales forecast for FULC is $0 with a range of ― to ―. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
